Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS APRIL ISSUE PUBLISHED
  • APRIL 2021 Issue has been successfully launched on 1 April 2021.

Abstract

BIOLOGICAL LICENSING APPLICATION VS DRUG LICENSING APPLICATION: COMPARISONS AND CONSEQUENCES

Sudheep Goud Sandhil, AfrasimMoin*, Jophy Johnson

ABSTRACT

The advancement in the medical sciences has led to the innovation of novel and complex formulations which includes unique combinations of drugs and biologics. The FDA has separate review process for a new drug and a biological product.Given these differences between the review processes for a new drug and biologic product, the designation of a combination drug as a drug or biologic product has often become critical. To avoid confusions in the review and designation process of a combination product, FDA has promulgated various guidelines assigning certain product classes to CDER or CBER and three intercenter agreements were made in the process. However, the FDA’s guidelines are not exhaustive and at times an individual designation is to be obtained from the office of communication products by submitting a Request for Designation (RFD). The RFD process is based on the Primary Mode of Action (PMOA), and the FDA provides ample guidance in how to determine the PMOA. This review article deals initially with an overview of approval process for a drug and a biologic product followed by comparisons of the same.This study aims at describing the methods followed by the FDA in designation process of a combination drug and also to list the alternative step of applying RFD for a combination product.Finally it concludes with the description of factors that influence the designation process of a combination drug with illustration of few examples.

Keywords: FDA, CDER,RFD, PMOA, Combination Product.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More